Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Backs Out Of Daclizumab Transplantation Deal With PDL

This article was originally published in The Pink Sheet Daily

Executive Summary

PDL is moving forward with Phase II development of the biologic in multiple sclerosis with partner Biogen Idec.
Advertisement

Related Content

PDL BioPharma Seeks Ularitide Partner That Grants Rights To A Late-Stage Drug
PDL BioPharma Seeks Ularitide Partner That Grants Rights To A Late-Stage Drug
Orphan Therapeutics Acquires Full Rights To Terlipressin From PDL BioPharma
Orphan Therapeutics Acquires Full Rights To Terlipressin From PDL BioPharma
PDL Focus Remains Nuvion, But 2007 Could Include Several Significant Deals
PDL Seeks Partner For Daclizumab In Asthma After Roche Backs Out
PDL Seeks Partner For Daclizumab In Asthma After Roche Backs Out

Topics

Advertisement
UsernamePublicRestriction

Register

PS063425

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel